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Abstract 
Evaluation of quality of care is an integral part of modern healthcare, and has 
become an indispensable tool for health authorities, the public, the press and 
patients. However, measuring quality of care is difficult, because it is a multifactorial 
and multidimensional concept that cannot be estimated solely on the basis of 
patients’ clinical outcomes. Thus, measuring the process of care through quality 
indicators (QIs) has become a widely used practice in this context. Other professional 
societies have published QIs for the evaluation of quality of care in the context of 
acute myocardial infarction (AMI), but no such indicators exist in Europe. In this 
context, the ESC Acute Cardiovascular Care Association (ACCA) has reflected on 
the measurement of quality of care in the context of AMI (STEMI and NSTEMI) and 
created a set of QIs, with a view to developing programmes to improve quality of care 
for the management of AMI across Europe. We present here the list of QIs defined by 
the ACCA, with explanations of the methodology used, scientific justification and 
reasons for the choice for each measure.  
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1. Introduction 
In a report published in 2001, the Institute of Medicine stated that “in its current form, 
habits and environment, American healthcare is incapable of providing the public with 
the quality health care it expects and deserves”(1). Evaluation of the quality of care is 
an integral part of modern healthcare, and has become an indispensable tool, much 
sought after by health authorities, the general public, the press and even patients 
themselves. However, measuring the quality of care is difficult, because it cannot be 
estimated solely on the basis of patients’ clinical outcomes, even if achieving a 
favourable outcome for the greatest number of patients possible is the ultimate goal 
of high quality care.  
Thus, measuring the process of care through quality indicators (QIs) or performance 
measures (PMs) has become a widely used practice in this context. The American 
College of Cardiology (ACC) and the American Heart Association (AHA) have 
considerable experience in the measurement of quality of care in the setting of AMI. 
Indeed, these two organisations have jointly published several Task Force 
documents and position papers with precise definitions of QIs and PMs that can be 
used to describe and evaluate management and outcomes of patients with acute 
coronary syndromes (ACS)(2). Furthermore, they have published several documents 
on the optimal methodology for defining QIs and PMs (3, 4), the statistics suitable for 
public reporting (5), and the use of composite indicators (6). The first set of PMs for 
AMI published by the ACC/AHA was released in 2006 (7), and updated in 2008 (8), 
and a position paper specific to coronary reperfusion published in 2008(9).  
The lack of standard definitions of QIs validated by the ESC for clinical situations 
such as AMI or heart failure is in stark contrast with the professional societies of 
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cardiology in the USA. Thus, the question arises as to whether it is time for the ESC 
to define QIs for AMI, which would be in line with the ESC’s own recommendations 
for the management of these conditions? The ESC Acute Cardiovascular Care 
Association (ACCA) has reflected on the measurement of quality of care in the 
context of AMI and aimed to create QIs, with a view to developing programmes to 
improve quality of care for the management of AMI across Europe.  
1.1.Objectives 
The objectives of the ACCA Quality of Care Working Group were to define suitable 
QIs for the management of AMI, with or without ST segment elevation. 
1.2. Scope 
Specifically, in an attempt to improve the management of patients hospitalised with 
AMI, the ACCA proposes standardisation of the evaluation of quality of care across 
all centres in Europe. Whilst the link between assessment and improvement of quality 
of care is a matter of debate, the hypothesis that improvement in quality partially 
relates to internal or external assessment is supported by observational data(10). 
Either way, the Quality of Care Working Group’s scope was to select not only QIs 
based on existing guidelines, but also to incorporate measures whose 
implementation is deemed to be important, like centre facilities, or patient 
satisfaction. Lastly, a set of simple and reliable QIs can be used to evaluate the 
conformity of actual practices with the ESC guidelines for management in AMI.  
The definition of QIs relies on the existence of treatments and strategies of proven 
efficacy, as well as on high-grade recommendations. These prerequisites are 
satisfied in several clinical situations, such as AMI, acute heart failure, pulmonary 
embolism, as well as chronic conditions including stable angina, coronary 
9 
 
revascularisation, atrial fibrillation, cardiovascular prevention, peripheral arterial 
disease and cardiac rehabilitation.  
1.3.Membership of the “Quality of Care Working Group” and selection of the 
domains of care. 
Under the supervision of the Board of the ACCA, a “Quality of Care Working Group” 
was formed and comprised international experts selected for their expertise in the 
management of patients with ACS. All members were invited to participate in the 
selection and definition of the QIs in the selected domains of management and were 
representative of the different European countries that comprise the ESC, and 
included members of the ACCA, members of the ESC Practice Guidelines 
Committee, and ad hoc members, experts in clinical practice, public health or 
statistics. The full list of the group leaders and members of the Quality of Care 
Working Group, with their respective area of expertise, is displayed in Table 1. 
Seven different domains of care where quality should be assessed were defined, with 
one chairperson responsible for coordinating the discussions in each domain. 
The aim of this selection was to extend the quality assessment beyond simply the 
process of care and its outcomes, by incorporating the full spectrum of the patient 
pathway, from organization of care, to outcomes and the patient experience. The 
seven domains selected are relevant to the clinical situation of AMI, namely: (i) centre 
organization, (ii) reperfusion/invasive strategy, (iii) in-hospital risk assessment, (iv) 
antithrombotic treatment during hospitalization, (v) discharge treatments, (vi) patient 
satisfaction, and (vii) composite QIs and outcomes.  
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2. Methodology 
2.1. Selection of Candidate Quality Indicators 
A set of 45 candidate QIs were identified, based on existing QIs and international 
guidelines for the management of STEMI and NSTEMI. These covered all seven pre-
selected dimensions. The 45 candidate QIs were selected by the Quality of Care 
Working Group using an online survey circulated to the whole group and completed 
by all members. Each candidate QI was graded on a scale of 1 to 5 according to the 
following criteria: (1) supported by evidence / guidelines, (2) interpretability, (3) 
actionability and room for improvement, (4) feasibility of assessment and (5) global 
fit.  
2.2. Definition of quality indicators 
For each domain, one or more “main” QIs, as well as one or more “secondary” QIs 
were finally retained. The grading of the QIs and the final selection of those to be 
retained was based on the feasibility and reliability of the assessment of the QI. The 
main QIs were selected because they were considered an essential element, 
mandatory for basic assessment. Conversely, the secondary QIs were considered as 
complementary measures that could be used to perform more advanced 
assessment, and/or may only be suitable for use in certain centres. The list of the 
main and secondary QIs for each domain is presented in Table 2, with details of the 
numerator and denominator, rationale, support from guidelines and method of 
reporting. The figure presents a summary of the QI in each domain, with the 
corresponding ESC guidelines. 
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2.3. Support 
The work is exclusively supported by the ACCA and the ESC. No commercial support 
was received for the development of the QIs.  
 
3. Quality Indicators for STEMI / NSTEMI 
 
3.1. Center Organization 
3.1.1. Dimensions of care 
For patients with AMI, early diagnosis, pre-hospital medical care, and quick access to 
revascularization through direct admission to cardiology centres with catheterization 
facilities available 24/7 have all been shown to reduce time to reperfusion, which in 
turn is associated with lower mortality(11). To this end, organized systems of care 
such as structured networks are needed to determine the optimal pathways of care 
based on local circumstances, centre characteristics and transfer capabilities in the 
area(12-14). Organization of networks of care has been shown to be effective in 
reducing times to reperfusion, through rapid diagnosis with expeditious ECG 
recording and interpretation, risk assessment, safe transfer and rapid access to 
reperfusion strategies(15-19). The main QI for network organization was based on 
four organizational points deemed to be the most important in clinical terms, as well 
as being easy to implement in practice, and easy to assess. Although non-written 
collaborations can be efficient in practice, the ACCA Quality of Care Working Group 
considers that only centres with a written protocol that has been discussed and 
signed by both the centre and the pre-hospital system should be regarded as 
participating in a network for the purposes of assessing quality of care.  
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3.1.2. Clinical relevance 
Organization of care has an important impact on the implementation of 
recommendations for times to reperfusion (13). Depending on the local environment, 
bringing the patient to the centre in a timely manner or bringing the treatment to the 
patient through the administration of intravenous fibrinolytics in the pre-hospital 
setting have been extensively discussed. Both methods are not exclusive and a well-
organized network organization should provide the most appropriate treatment in the 
shortest delay (20). Several reports relate network experiences, and all have shown 
an improvement in the proportion of patients reperfused in a timely manner thanks to 
a single call number, a physician-staffed or trained paramedic ambulance crew and 
direct transfer to a PCI-capable hospital with experienced cardiologists on call. The 
Vienna citywide system of care involves one academic and four non-academic 
centres, providing a physician-staffed ambulance and a guarantee that only 
experienced interventionists are on duty (21). The French SAMU organization has a 
physician-staffed ambulance on site and can start pre-hospital fibrinolytic therapy, 
antithrombotic therapy, resuscitation and transfer directly to PCI-capable centres 
(22). Based on similar organizations, numerous other networks have been 
established in large cities (23-25), regions (23) or nations (26).  
3.1.3. Specific aspects for potential quality indicators 
Optimal treatment delivered within a minimal time frame has been shown to reduce 
mortality in STEMI patients and is thus strongly recommended by guidelines(27-29). 
The main effective components of a STEMI network are pre-hospital ECG recording 
and interpretation(30-33), pre-hospital activation of the catheterization laboratory(34, 
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35) with a single call number(7, 36), adequate selection of the mode of 
transportation(37), and direct admission to the catheterization laboratory(19). All 
these strategies have been identified as predictors of short door-to-balloon times(38). 
This type of optimal collaboration within a STEMI network has been shown to 
increase both the proportion of patients treated by reperfusion, and the proportion of 
patients with timely reperfusion(20). 
Prospective monitoring of the times to management in STEMI patients:  
Since the time to reperfusion is clinically important and is used to define the QI for 
reperfusion, the different times to management need to be recorded. Although the 
most clinically important overall time span is the time from symptom onset to 
reperfusion (that is, the total ischemic time), several intermediate times are required, 
such as: time of the call, time to first medical contact, time of the first ECG, time of 
arrival at the PCI-capable centre (door), time of the balloon (guidewire or other 
device) that restores patency in the infarct-related artery. Additionally, for patients 
admitted to non-PCI centres, the interval between time of admission and time of 
discharge for transfer to a PCI-capable centre (door in - door out time) needs to be 
recorded. 
 
The ESC guidelines recommend participation in a national or international registry or 
a quality program, such as the “Stent for Life” initiative (39), to record data regarding 
the actual management of patients admitted with AMI. Despite a lack of firm evidence 
that participation in a registry has an impact on quality of care, the ACCA Quality of 
Care Working Group considers that regular participation in a registry which assesses 
quality of care is an indicator of quality at a centre level. 
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3.1.4. Definition of the main and secondary quality indicator for “Center Organisation” 
Name of the 
Main QI 
The centre should be part of a Network Organization with 
written protocols for rapid and efficient management covering 
the following points: 
 Single emergency phone number for the patient to be 
connected with a medical system for triage  
 Pre-hospital interpretation of ECG for diagnosis and 
decision for immediate transfer to a centre with 
catheterization laboratory facilities 
 Pre-hospital activation of the catheterization laboratory  
Name of the 
Secondary QI 
(1) 
Routine assessment of relevant times for the reperfusion 
process in STEMI patients (i.e. recording actual times in order 
to assess “call to first medical contact”, “first medical contact to 
door”, “door to device” and “door-in door-out” for centres 
without cath-lab on site). 
 
Name of the 
Secondary QI 
(2) 
The centre should participate in a regular registry or program 
for quality assessment 
 
3.1.5. Agreement with guidelines and existing quality indicators 
Main QI: The guidelines for the management of STEMI issued by the ESC explicitly 
recommend that each center receiving patients with suspected AMI should be part of 
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a Network Organization. According to the ESC guidelines, the main features of the 
network are (1) the existence of written protocols for risk stratification and adequate 
transportation, (2) pre-hospital triage with the aim of bypassing non-PCI hospitals, (3) 
immediate transportation to the catheterization laboratory for eligible STEMI patients, 
(4) monitoring and immediate transfer of STEMI patients admitted to non-PCI 
centres. In view of the guidelines recommendations, the components of the 
Structure-Network QI are strongly supported. 
The ACC/AHA PM for STEMI and Non-STEMI do not include any Structure-Network 
QI. The Canadian Cardiovascular Society (CCS) PM refers to “system indicators” that 
contain a pre-hospital 12 lead ECG (40). 
Secondary QIs: The ESC guidelines for both STEMI and NSTE-ACS recommend 
participation in a survey or registry, both to record times to reperfusion among STEMI 
patients(28) and to record the degree of application of guidelines for all patients with 
STEMI and NSTE-ACS, as is already undertaken by a number of national initiatives, 
such as in Sweden (through the Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease Evaluated According to 
Recommended Therapies, SWEDEHEART), the UK (Myocardial Infarction National 
Audit Project, MINAP) registry), Germany, Italy and Israel on a regional basis, or 
through intermittent programs in other countries (French Registry on Acute ST-
elevation and non ST-elevation Myocardial Infarction, FAST-MI). The underlying 
justification for this recommendation is that continuous monitoring of actual patient 
management may enhance the quality of treatment and minimize unwarranted 
variation in evidence-based care.  
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3.2. Reperfusion/invasive strategy 
3.2.1. Dimensions of Care 
Invasive strategy, myocardial revascularisation, and the speed with which it is 
achieved, are key elements in the management of patients with ACS. However, the 
approach is different depending on the clinical presentation of the ACS, namely 
STEMI or NSTEMI, the myocardium at risk and the ischemic time. 
In patients with STEMI admitted during the first few hours after symptom onset, the 
choice of reperfusion strategy and the speed with which it is implemented have a 
major impact on clinical outcomes(41, 42). Given this, coronary reperfusion 
performed within a short time frame is recommended (29, 42, 43). Both the use of 
reperfusion (either by fibrinolytic therapy in eligible patients or by PCI) and its timely 
implementation have previously been used as indicators of quality of care (8, 9). 
Many opportunities exist to reduce the proportion of patients who do not receive 
reperfusion, and the delay with which this is provided. This requires active 
involvement from all partners involved along the management pathway, and includes 
high quality organisation of care within a network organisation (7, 25). Accountability 
is an important factor in measuring quality of care, and measuring the different 
components of the overall time to reperfusion (such as time of call, time of first 
medical contact, time of arrival, transfer, arterial puncture, time at which artery 
patency is achieved) makes it possible to rank the quality of each in the overall 
pathway of care, and identify areas where there may be room for improvement (44).  
In patients with NSTEMI, an invasive strategy using coronary angiography with a 
view to myocardial revascularisation is also related to lower mortality in moderate-to-
high and in high risk patients (45, 46). In NSTEMI, appropriate use of an invasive 
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strategy is linked to the assessment of the patient’s ischemic and bleeding risks. In 
practice, according to the risk profile, invasive strategy must be immediate (<2 
hours), early (<24 hours), <72 hours or conditional. Avoiding the risks of an invasive 
strategy for patients at low ischemic risk is equally as important as ensuring access 
to invasive strategy for patients at high ischemic risk.  
 
3.2.2. Clinical relevance 
For patients with STEMI, the relation between shorter times to reperfusion and 
mortality has previously been established, particularly within the first 3-4 hours after 
onset of infarction. Beyond 12 hours, the benefit of reperfusion is less well 
established, and although PCI is recommended within the first 24 hours, measures of 
quality of care are limited to patients admitted less than 12 hours since the onset of 
symptoms(47, 48). The benefit is greater when reperfusion is performed early. The 
advantage of earlier reperfusion is seen more in the first 3-4 hours after onset of 
symptoms. The estimated times to reperfusion also contribute largely to the choice of 
reperfusion strategy. PCI is the technique of choice except if it is estimated that it 
cannot be performed within 120 minutes after the diagnosis of STEMI has been 
established(29, 42, 49). A time to reperfusion therapy ≤ 30 minutes (diagnosis to 
injection) is recommended when fibrinolytic therapy is the strategy of choice; and 
when PCI is the chosen strategy, the recommended time to PCI is ≤ 120 minutes 
between diagnosis and opening of the infarct-related artery. When the door to 
balloon (or to first device that open the artery) time is considered, ESC guidelines for 
revascularization propose a recommended time < 60 mins. 
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For patients with NSTEMI, the benefit of an invasive strategy is established only in 
patients at risk of ischemia(45, 46, 50). An invasive strategy is needed to confirm the 
diagnosis of ACS, identify the culprit coronary lesion, establish the indication for 
revascularization (by PCI or surgery) and assess the long-term risk. The timing of the 
invasive strategy also depends on risk assessment; a small proportion of patients 
require an immediate invasive strategy (within 2 hours), an early invasive strategy 
(within 24 hours) is indicated for high risk patients, while an invasive strategy can be 
performed within 72 hours in NSTEMI patients without high risk criteria. Lastly, a 
selective invasive strategy can be used among patients at low ischemic risk, 
according to the results of their non-invasive stress test. A decision for an early 
invasive strategy (i.e. performance of a coronary angiography and revascularization if 
appropriate) versus a conditional invasive or medical strategy should take into 
account the risk-benefit ratio. Invasive treatment is recommended in the presence of 
ischemic risk factors, and conversely, is not recommended in the absence of 
ischemic risk factors(27, 29).  
 
3.2.3. Specific aspects for potential quality indicators 
For the QIs relating to reperfusion and invasive strategy, the numerator and 
denominator should comprise all patients hospitalized with STEMI or NSTEMI. Only 
patients eligible for the invasive approach should be included, and form both the 
numerator and the denominator. Therefore, the numerators and denominators should 
not include patients who have contraindications, such as patients with STEMI who 
present after the first 12 hours, or those who have clinical, allergic, arterial access, or 
hemorrhagic problems, or patient-related reasons for exclusion (refusal to provide 
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consent for angiography or PCI). Patients with clinical or patient-related reasons for 
exclusion are considered ineligible. 
 
In STEMI patients, measuring time to reperfusion requires that the different times of 
the various stages along the management pathway be measured. Both the use of 
reperfusion (either by fibrinolytic therapy in eligible patients or by PCI) and its timely 
implementation can be used as indicators of quality of care (8, 9). In case of 
fibrinolysis, the time interval to initiation of fibrinolysis is counted from first medical 
contact to injection, which is in line with recommendations for pre-hospital fibrinolysis. 
Conversely, in case of reperfusion by primary PCI, if the patient is admitted directly to 
a PCI-capable centre, the door to balloon time is preferred over other starting time 
points, in order to better reflect internal hospital organization, and also because it is 
easier to measure. Finally, if the patient is admitted to a centre without PCI facilities 
and primary PCI is chosen as the reperfusion strategy, the door-in-door-out time in 
the non-PCI-capable centre has been selected, as it is independent of geographical 
constraints that may affect transfer times.  
Lastly, the median time from FMC to passage of the device that achieves reperfusion 
of the infarct-related artery has been chosen as a secondary QI.  
 
In NSTEMI, appropriate use of an invasive strategy is linked to the assessment of the 
patient’s ischemic and bleeding risks. Thus, according to the risk profile, invasive 
strategy must be immediate (<2 hours), early (<24 hours), <72 hours or conditional. 
To avoid excessive complexity, only the decision to perform an invasive strategy 
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within the first 72 hours in NSTEMI patients without contraindication has been 
retained as a QI.  
 
3.2.4. Definition of the main and secondary quality indicators:  
Name of the Main 
QI  
(STEMI 1) 
Proportion of STEMI patients reperfused among those eligible 
(onset of symptoms to diagnosis <12h)  
Name of the Main 
QI (STEMI 2) 
The proportion of patients reperfused within the timeframe 
recommended by the ESC guidelines; these time frames 
vary according to whether fibrinolysis or PCI is chosen as 
the strategy of choice.  
o For fibrinolysis, a maximum time delay of 30 
minutes between first medical contact 
(diagnosis) and the start of injection is retained.  
o For primary PCI, a maximum door to balloon 
time of <60 minutes is retained for patients 
admitted to centres with PCI facilities on site.  
o For transferred patients, an additional QI is 
defined, namely a “door-in, door-out” time of 
less than 30 minutes.   
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Name of the 
Secondary QI  
Diagnosis to passage of wire  time (absolute value) for primary 
PCI.  
 
Name of the 
Main QI 
(NSTEMI 1)  
Proportion of patients with NSTEMI, and no contra-indication, 
who receive coronary angiography within 72 hours after 
admission  
 
3.2.5. Agreement with guidelines and existing quality indicators:  
STEMI patients. The ESC guidelines stipulate that all patients with STEMI of onset 
<12 hours should receive reperfusion therapy as early as possible. In addition, the 
ESC guidelines recommend measuring the time from the onset of symptoms, FMC, 
diagnosis, and initiation to reperfusion, stating that an invasive strategy should be 
performed within 90 minutes in early presenters with a large area at risk(49). 
Two main QIs and one secondary QI have been defined for myocardial reperfusion:  
 Main QI (STEMI 1) is the percentage of patients reperfused among patients 
admitted with STEMI of <12 hours duration. This QI is identical to the PM defined 
by the ACC/AHA Task Force in 2008(8, 9). 
 Main QI (STEMI 2) is the percentage of patients reperfused within the timeframe 
recommended by the ESC guidelines; these time frames vary according to 
whether fibrinolysis or PCI is the strategy of choice.  
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o For fibrinolysis, a maximum time delay of 30 minutes between FMC 
(diagnosis) and the start of injection is retained, in accordance with the 
ESC guidelines.  
o For primary PCI, a maximum door to balloon time of <60 minutes is 
retained for patients admitted to centres with PCI facilities on site.  
o For transferred patients, an additional QI is defined, namely a “door-in, 
door-out” time of less than 30 minutes.   
The 2008 ACC/AHA PM related to reperfusion in STEMI were: (1) time to fibrinolytic 
therapy, (2) time to primary PCI, (3) proportion of patients who received reperfusion 
therapy, (4) time from emergency department arrival at STEMI referral facility to 
emergency department discharge for transfer to PCI centre and (5) time from 
emergency department arrival in PCI-centre to PCI. In the most recent ACC/AHA 
Task Force defining PM for reperfusion, five other PMs for reperfusion were defined. 
The main PM was the time to device use for PCI and four proposals for future PM 
relating to time to reperfusion were also defined: (1) time to reperfusion among 
patients transferred for PCI, (2) proportion of reperfusion-eligible patients receiving 
therapy, (3) diagnosis to reperfusion and (4) time to reperfusion for patients 
developing STEMI in the hospital(8, 9). The ACCA Quality of Care Working Group 
QIs are in agreement with these indicators from the ACC/AHA, but only three are 
retained in our document. Times are used with threshold values, according to the 
type of reperfusion and the need for transfer. The diagnosis to balloon time was left 
as an absolute value, because even though this measure depends on numerous 
factors, it is the most important in clinical terms(43). 
NSTEMI patients: Although international guidelines concur in their recommendations 
of an invasive strategy among patients with high-risk features(27, 29), this aspect of 
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management has never before been used in measures of quality of care. To avoid 
excessive complexity, the decision to perform an invasive strategy within the first 72 
hours in NSTEMI patients without contraindication was selected as a QI.  
 
3.3. In-hospital risk assessment 
3.3.1. Dimensions of care 
Clinical outcomes following AMI are highly variable, and are, in part, due to the wide 
spectrum of baseline clinical risk levels. Therefore, risk assessment is a key step in 
the management of patients with AMI, particularly their risk of death and recurrent MI 
(to determine the need for a more aggressive approach), the risk of iatrogenic 
complications such as bleeding (to modify the use of antithrombotic treatments) and 
the short- or long-term risk of heart failure (to enable tailoring of clinical review, 
investigations and guideline-indicated therapies). 
Establishing the risk of in-hospital or short-term death from the ischemic process will 
better inform clinicians of necessary changes to an invasive strategy, namely its 
timing. Indeed, for NSTEMI, the clinical benefit of an early invasive strategy has been 
shown to be related to the level of ischemic risk, with greater clinical benefits seen in 
higher risk patients. 
Bleeding is one of the main iatrogenic complications among patients with AMI and is 
associated with an adverse prognosis. Bleeding risk estimation can help define the 
best diagnostic and therapeutic strategy and should affect the type, dose and 
duration of antithrombotic treatments, as well as the choice of arterial access for 
invasive procedures.  
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Assessment of left ventricular function and the quantification of resting left ventricular 
ejection fraction (LVEF) before discharge from hospital are important for the selection 
of patients with severe left ventricular dysfunction who may benefit from additional 
treatments. Left ventricular systolic dysfunction is a key predictor of immediate and 
late episodes of heart failure, and ventricular arrhythmia(51). Patients with severe left 
ventricular dysfunction require specific secondary prevention therapies.  
For STEMI, with the increasing use of primary PCI, risk assessment for ischaemia 
before discharge has become less important. This is because it can be assumed that 
the infarct-related coronary lesion has been treated and stabilized, and the presence 
or absence of significant lesions in other arteries has been assessed. 
3.3.2. Clinical relevance 
Observational studies support the use of established risk scores for ischaemic and 
bleeding risk.  
Ischemic risk. Of the numerous ischaemic risk scores, the GRACE risk score is not 
widely used, but is strongly endorsed by ESC guidelines (27, 28). A recent update of 
the GRACE score (GRACE V2.0), calculated from 32,307 patients enrolled between 
2001 and 2007 with suspected ACS, has shown, in an external population, adequate 
discrimination and calibration for in-hospital and 3 year mortality(52). Categorization 
of the patients into GRACE high risk, GRACE medium risk and GRACE lower risk 
may help physicians in their choice of whether to pursue an invasive strategy, since 
the invasive approach mainly benefits high risk patients(53, 54). Studies from 
registries have shown that the use of coronary angiography is higher in individuals at 
lower risk as compared to those at higher risk, defining the ‘treatment-risk 
paradox’(55, 56), Employing a facilitated GRACE score, like the updated one, has the 
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potential to favor a systematic and objective evaluation of the ischemic risk of 
NSTEMI patients and to increase the rate of revascularization in high-risk patients 
without contraindications. This means that, based on the impact of a systematic 
interventional strategy in the randomized trials, there would be between 30 and 80 
fewer cardiovascular deaths or MIs for every 10,000 patients with NSTEMI (45, 57-
60). 
Bleeding risk can be predicted from baseline variables through a specific risk score. 
Bleeding risk scores have also been developed from registry or trial cohorts in the 
setting of AMI and PCI. The Can Rapid risk stratification of Unstable angina patients 
Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines 
(CRUSADE) bleeding risk score (http://www.crusadebleedingscore.org) was 
developed from a cohort of 71,277 NSTE-ACS patients (derivation cohort) and further 
validated (61). The CRUSADE bleeding score has been demonstrated to have a 
good predictive accuracy also in STEMI patients treated by primary PCI(62). 
Assessment of infarct size and post MI left ventricular systolic function can be 
performed by echocardiography, a technique available in almost all centres admitting 
patients with AMI. 
3.3.3. Definition of the quality indicators:  
Name of the 
Main QI (1)  
Proportion of ischemic risk assessment using the GRACE 
risk score for patients with NSTEMI. GRACE score should be 
assessed and the numerical value of the score recorded for all 
patients admitted with suspected NSTEMI.  
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Name of the 
Main QI (2)  
Bleeding risk assessment using the CRUSADE risk score. 
CRUSADE bleeding score should be assessed and the 
numerical value of the score recorded for all patients admitted 
for NSTEMI. 
 
Name of the 
Main QI (3)  
Assessment of LVEF before discharge. LVEF should be 
assessed and numerical value recorded for all patients 
admitted with STEMI and NSTEMI. 
 
3.3.4. Agreement with guidelines and existing quality indicators 
Main QI (1): Ischaemic risk assessment. ESC NSTE-ACS guidelines recommend 
basing diagnosis and initial short-term ischaemic and bleeding risk stratification on a 
combination of clinical history, symptoms, vital signs, other physical findings, ECG 
and laboratory results. The quantitative assessment of ischaemic risk scores is 
superior to clinical assessment alone. The GRACE risk score provides the most 
accurate stratification of risk both on admission and at discharge and has a Class IA 
recommendation. 
In the ACC/AHA PM set, risk assessment is used to measure the risk-adjusted 30- 
day mortality, but does not itself represent a PM. 
Main QI (2): Bleeding risk assessment. The ESC NSTE-ACS guidelines stipulate that 
the use of the CRUSADE bleeding risk score may be considered in patients 
undergoing coronary angiography to quantify bleeding risk with a Class B IIb 
recommendation. Bleeding risk assessment is also recommended in the ESC STEMI 
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guidelines for antiplatelet therapy (like abciximab and prasugrel), without mention of 
any type of score for this assessment.  
In the ACC/AHA PM for STEMI/NSTEMI, no assessment of bleeding risk is stated. 
Main QI (3): Evaluation of left ventricular systolic function is recommended by the 
ESC guidelines for STEMI (Class I B) and for NSTE-ACS (Class I C). Assessment of 
left ventricular systolic function has been a part of the ACC/AHA PM set since 2008.   
 
3.4. Anti-thrombotic treatment during hospitalisation 
3.4.1. Dimensions of care 
Anti-thrombotic treatment has a pivotal role in the management of AMI(63). 
Therefore, the combination of an anticoagulant with antiplatelet therapy is mandatory 
in the treatment of AMI(27-29). This approach has been shown to reduce mortality 
(both cardiovascular and total), (re)infarction and stroke(64-69). Moreover, many 
patients with AMI are treated with PCI and stent implantation, and in this case dual 
antiplatelet therapy (DAPT) has a key role in reducing stent thrombosis, both in the 
short (acute/subacute) and long term. Finally, antiplatelet therapy improves long-term 
outcomes following AMI. Prolongation of DAPT beyond the first year is currently a 
matter of debate(70, 71).  
3.4.2. Clinical relevance 
Antiplatelets: The benefit of aspirin for AMI has been demonstrated in four 
randomized studies, with the rate of ischaemic events reduced by half as compared 
to placebo. The benefit of the combination of aspirin with clopidogrel has also been 
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demonstrated, leading to a high-grade recommendation for DAPT(27-29). More 
potent P2Y12 platelet receptor inhibitors (prasugrel and ticagrelor), in addition to 
aspirin, are linked to improved outcomes, with a reduction in the composite ischaemic 
outcome, including mortality from STEMI(72-74). The increase in bleeding is 
reasonable and sometimes negligible(75), with the exception of some high-risk 
subgroups. Based on trial design, prasugrel use has been limited to selected STEMI 
patients who receive PCI and who do not have previous stroke(73). Ticagrelor is 
suitable for use among a broader ACS population, irrespective of history, use of PCI 
or pre-treatment with clopidogrel(72). Whatever the drug chosen for P2Y12 inhibition, 
DAPT should be initiated as soon as the diagnosis is established, and continued for a 
duration of 12 months, unless bleeding complications occur(76). The benefit of using 
glycoprotein GPIIb/IIIa inhibitors was established before the advent of DAPT, but 
since strong P2Y12 platelet receptor inhibitors have become available, the use of 
GPIIb/IIIa inhibitors has been reserved for patients with peri-procedural thrombotic 
complications and patients with a high risk of thrombosis and a low risk of bleeding.  
Anticoagulation: A parenteral anticoagulant is required during the acute phase, and 
continued until completion of revascularization or hospital discharge, whichever 
occurs first. Due to multiple comparisons of a variety of anticoagulants, at different 
doses, with or without arterial access and associated with different combinations of 
antiplatelets, no specific single anticoagulant regimen can be proposed for STEMI 
(unfractionated heparin, the low molecular weight heparin enoxaparin, and to some 
extent, bivalirudin have been investigated in prospective randomized trials). 
Conversely, for NSTEMI, fondaparinux at a dose of 2.5 mg/day is considered by 
guidelines to have a favorable efficacy/safety profile, except in those proceeding 
directly to PCI(27-29, 77-79).  
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3.4.3. Specific aspects for potential indicators 
The complexity of selecting appropriate antithrombotic treatment, and the high-grade 
recommendations suggest that the selection of antiplatelet therapy and 
anticoagulants is an ideal field for the assessment of the quality of care.  
Antiplatelet agents at admission: Aspirin, initiated as soon as possible in all patients 
without contraindication, has been used as a QI, both at admission and at discharge. 
Nevertheless, since the rate of use of aspirin is often higher than 95%, the interest of 
keeping this indicator is debatable. As regards P2Y12 inhibitors, the choice between 
clopidogrel, prasugrel and ticagrelor is underpinned by clear contraindications, 
limitations of use, and risk assessment, and therefore might also reflect quality. 
Ticagrelor is recommended over clopidogrel unless the patient is at high risk of 
bleeding (patients with previous haemorrhagic stroke, chronic oral anticoagulation or 
fibrinolytic therapy, ongoing bleeding). Prasugrel is also recommended over 
clopidogrel in patients undergoing PCI, but also without a history of any type of 
cerebrovascular accident, age <75 years and body weight ≥60 kg (73). When neither 
ticagrelor nor prasugrel is possible, clopidogrel is the best option. The use of 
GPIIb/IIIa inhibitors is decided case by case, according to criteria that are not always 
recorded and, therefore, is less suitable for quality assessment. 
Antiplatelet agents at discharge: The prescription of DAPT at discharge, for an 
expected duration of one year, is well supported by guidelines, and applicable to AMI 
irrespective of its management. The choice of P2Y12 inhibitor follows the same rules 
as at admission. In addition, DAPT prescription at discharge was suggested as a 
potential QI in the recent ESC 2015 NSTE-ACS guidelines (27), without distinction of 
any single P2Y12 inhibitor molecule. Only patients treated by chronic anticoagulants 
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are excluded, due to a high bleeding risk, a lack of scientific evidence, and a lack of 
strong recommendation regarding discharge antiplatelet treatment. 
Anticoagulants. The use of fondaparinux in patients with NSTEMI (except those 
proceeding directly to PCI or those with severe renal dysfunction) can be used as a 
QI. If fondaparinux is not available, enoxaparin should be preferred. In STEMI 
patients, the use of anticoagulant prescription to assess quality is challenging, due to 
the multiplicity of drugs, doses and possible combinations. Dosing errors or 
inappropriate combinations of different anticoagulants are associated with thrombotic 
or haemorrhagic complications and could be tracked for quality assessment.  
3.4.4. Definition of the main and secondary quality indicators for “antithrombotic 
treatments during hospitalisation” 
Name of the 
Main QI (1)  
Proportion of patients (numerator and denominator detailed in 
appendix) with “adequate P2Y12 inhibition” defined as: number 
of patients discharged with prasugrel or ticagrelor or 
clopidogrel / patients eligible. Eligible is defined as follows:  
 For ticagrelor = AMI patients without previous 
haemorrhagic stroke, high bleeding risk, fibrinolysis or 
oral anticoagulation. 
 For prasugrel: PCI treated AMI patients without previous 
haemorrhagic or ischemic stroke, high bleeding risk 
(patients > 75 years and/or <60 kg body weight are also 
considered as high bleeding risk), fibrinolysis or oral 
anticoagulation.   
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 For clopidogrel: if no indication for prasugrel or ticagrelor 
and no high bleeding risk. 
 
Name of the 
Main QI (2)  
Proportion of patients with NSTEMI treated with fondaparinux, 
unless candidate for immediate (< 2 hours) invasive strategy or 
with eGFR < 20 ml/min. 
 
Name of the 
Secondary QI   
Proportion of patients discharged on dual antiplatelet therapy / 
patients with AMI, without clear and documented 
contraindication 
 
3.4.5. Agreement with guidelines and existing quality indicators 
For STEMI patients who receive fibrinolysis, aspirin and clopidogrel have class IB 
and IA indications, respectively. Enoxaparin has the best indication with fibrinolysis 
(IA), followed by UFH (IC). In STEMI patients treated with primary PCI, prasugrel and 
ticagrelor both have a Class IB recommendation, while clopidogrel is indicated only if 
prasugrel and ticagrelor are not available or contraindicated (Class IC). The 
recommendations for parenteral anticoagulants are IC for UFH, IIaA for bivalirudin 
and IIaB for enoxaparin. 
For NSTEMI patients, antiplatelet therapy with prasugrel or ticagrelor has a class IB 
recommendation, while clopidogrel is indicated in patients who cannot receive 
prasugrel or ticagrelor or who are treated with oral anticoagulants. In patients naive of 
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P2Y12 inhibitors undergoing PCI, cangrelor has a lower level of recommendation 
(IIbA). 
Previous ACC/AHA PMs have not considered any PM related to anti-thrombotic 
therapy. However, in the 2008 update of PM for STEMI/NSTEMI, the use of 
clopidogrel in medically treated AMI patients only, as well as excessive initial dose of 
unfractionated heparin, enoxaparin, abxicimab, eptifibatide and tirofiban, were 
considered as “test measures”. In addition, the use of a standardized protocol for 
anticoagulants, and a tracking system for anticoagulation errors, were also 
considered as PMs in test(8).   
 
3.5. Secondary prevention - discharge treatments 
3.5.1. Dimension of care 
The secondary prevention of cardiovascular events following index AMI is critical, 
because patients remain at high risk of mortality and recurrent cardiovascular events 
long after an AMI. Long-term cohort studies have shown that mortality after 
hospitalization with AMI is high (45). Moreover, secondary prevention 
pharmacotherapy has been shown to reduce long-term adverse clinical outcomes in 
this group (80-82). While the long-term management of patients with AMI is 
predominantly the responsibility of the general practitioner, secondary prevention 
medications will have a greater chance of being implemented if performed during the 
hospital stay. The caveat to this is that with declining lengths of hospital stay(83), 
there is less of a distinction between acute and chronic therapies and it is therefore 
the shared responsibility of primary and secondary care physicians to ensure that all 
eligible patients with AMI are prescribed and maintained on guidelines-indicated 
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medications. This domain encompasses the prescription of statins, angiotensin-
converting enzyme inhibitors (ACEIs)/ angiotensin receptor blockers (ARBs) and 
beta-blockers.  
3.5.2. Clinical relevance 
The benefit of long-term treatment with beta- blockers among patients with AMI who 
have heart failure or left ventricular systolic dysfunction is well established(80). 
However, there are no contemporary randomized controlled trials testing the efficacy 
of beta-blockers among patients following AMI without HF. As such, current ESC 
guidance is to prescribe beta-blockers to hemodynamically stable patients who are 
eligible and who have a LVEF ≤0.40. For ACEIs/ARBs, there is also strong evidence 
for their use as secondary prevention therapy among eligible patients with AMI who 
have heart failure or a LVEF ≤0.40(81, 82, 84). Compelling evidence supports the 
use of high intensity statins for reducing recurrent cardiovascular events and mortality 
following AMI (85, 86), and although the rate of prescription of statins at discharge 
from hospital is high (83,88,89), a substantial proportion of patients are not 
discharged with high intensity statins after hospitalization for coronary heart disease 
(87). This is important when high intensity statins reduce low-density lipoprotein 
(LDL) cholesterol by around 50% and the efficacy of statins is apparent across a 
range of patient groups, including both sexes, the young and the elderly, as well as 
those with and without diabetes. As with statins, the opportunity to reduce premature 
cardiovascular death through increased prescription of ACEI/ARB and beta-blockers 
is clearly apparent (83, 88-90).  
The magnitude of the relationship between high intensity statin therapy and mortality 
is strong. In 4162 patients hospitalized with an acute coronary syndrome, higher 
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intensity statins were associated with a 16% reduction in the risk of death at 2 years, 
over and above that of the reduction in risk of death associated with standard lipid 
therapy (85). The magnitude of the relationship between ACEIs/ARBs and mortality 
among patients with AMI is strong (81). For beta-blockers, the magnitude of the 
relationship for mortality among patients with AMI is weaker. That is, there are no 
contemporary randomized data testing the efficacy of beta-blockers among patients 
with AMI who do not have heart failure, and recent data from an observational study 
suggested no benefit among this group. In the CAPRICORN randomized trial of 1959 
patients with AMI and a LVEF <0.40, the risk of all-cause mortality or non fatal AMI at 
a mean of 1.3 years was reduced by 29% among patients who received carvedilol 
(80). However, for patients with AMI and HF or a reduced LVEF, the magnitude of the 
evidence is strong. In a randomized trial of 2647 patients with heart failure, of which 
half had documented ischaemic heart disease, bisoprolol significantly reduced all-
cause mortality by 34% at a mean of 1.3 years (91). 
 
3.5.3. Specific aspects for potential quality indicators 
For the secondary prevention medication QIs, the numerator and denominator should 
comprise all patients hospitalized with AMI. Only patients eligible to receive the 
medications should be included, and form both the numerator and denominator. 
Therefore, the numerators and denominators should not include patients who are 
allergic, have contraindications, refuse, or have side effects from the medications – 
these patients are ‘ineligible’.  
Specifically, for the statins indicator, the numerator must only include patients who 
are prescribed a high intensity statin (such as atorvastatin 40-80 mg or rosuvastatin 
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20 mg) (92) at discharge. Consequently, patients who receive a low-intermediate 
intensity statin after hospitalization will be included in the denominator and not in the 
numerator. Patients with a history of intolerance to high-intensity statin therapy or 
have other characteristics that may influence safety should not be included in the 
numerator or denominator.  
For ACEIs/ARBs, the numerator and denominator include all eligible patients with 
AMI who have heart failure or a LVEF ≤0.40. Ineligibility criteria for the numerator and 
denominator include hypotension, acute renal failure and hyperkalemia (the 
contraindication must be documented in the patient’s file). Specifically, the numerator 
is the number of patients with AMI and heart failure or a LVEF ≤0.40 who are 
prescribed an ACEI or an ARB.  
Regarding beta-blockers, both STEMI and NSTE-ACS ESC guidelines are in 
alignment. Therefore, the numerator and denominator should comprise eligible 
patients with either heart failure or a LVEF ≤0.40. Ineligibility criteria for beta-blockers 
include evidence of a low output state, increased risk for cardiogenic shock, PR 
interval >0.24 seconds, second- or third-degree heart block, active asthma, or 
reactive airways disease. Therefore, the numerator will comprise the number of 
patients with AMI who have heart failure or a LVEF ≤0.40, who have no ineligibility 
criteria, and who are prescribed a beta-blocker, whereas the denominator is defined 
as the number of patients with AMI who have heart failure or a LVEF ≤0.40, and who 
have no ineligibility criteria.  
3.5.4. Definition of the main and secondary quality indicators for “secondary 
prevention – discharge treatments” 
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Name of the 
Main QI   
Proportion of patients with AMI discharged on statins, 
unless contra indicated, at high intensity (defined as 
atorvastatin ≥40 mg or rosuvastatin ≥20 mg). 
 
 
Name of the 
Secondary QI 
(1)  
Proportion of patients with  AMI and clinical evidence of 
heart failure or a LVEF ≤  0.40 who are prescribed, at 
discharge, an ACEI (or ARBs if intolerant of ACEI) unless 
contraindicated.  
 
 
Name of the 
Secondary QI 
(2)  
Proportion of patients with  AMI  and clinical evidence of 
heart failure or an LVEF ≤ 0.40 who are prescribed, at 
discharge, beta-blockers, unless contraindicated.  
 
 
3.5.5. Agreement with guidelines and existing quality indicators 
Currently, the use of high intensity statins initiated early after admission to hospital 
(the main QI) is supported by the ESC guidelines (Class 1A) and ACC/AHA 
guidelines for STEMI (1B) and NSTEMI (Class1)(27, 28, 93, 94). The secondary QI, 
the use of an ACEi (or ARB if intolerant of ACEI) unless contraindicated, before 
discharge in patients with clinical evidence of heart failure or a LVEF ≤ 0.40 is also 
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supported by the ESC and ACC/AHA guidelines (Class 1A). The other secondary QI, 
the use of a beta-blocker, unless contraindicated, before discharge in patients with 
clinical evidence of heart failure or a LVEF ≤ 0.40 is supported by the ESC guidelines 
(Class 1A) and ACC/AHA guidelines for STEMI (Class 1A) and NSTEMI (Class 1B).  
 
3.6. Patient satisfaction 
3.6.1. Dimensions of care 
The Institute of Medicine has considered that being “respectful of and responsive to 
individual patient preferences, needs and values and [ensuring] that patients guide all 
clinical decisions” is a key element of the quality of care (1). Measuring patient 
satisfaction, as well as patient reported outcomes, provides information about 
symptoms, health-related quality of life, morbidity and satisfaction with care that are 
reported directly by the patient and not captured in medical records.  
The ESC recognized the importance of including patient reported outcome measures 
(PROMs) in clinical trials and research to inform patients, clinicians, payers and 
policy-makers (95). PROMs provide information about health-related quality of life 
that can be used to assess how a treatment can improve symptoms or functional 
capacity, in association with other clinical endpoints such as clinical events or 
morbidity (96). This aspect of the quality has been measured through the patient 
satisfaction QI. Patient satisfaction informs about important aspects of the quality of 
management, such as fast access to reliable health advice, effective treatment and 
information delivered by health professionals, continuity of care and smooth 
transitions and emotional support, empathy and respect (97-99). Thus, patient 
satisfaction is an essential and complementary approach to conventional quality of 
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care indicators. This is the first time that PROMs have been considered in QIs for 
AMI. 
3.6.2. Clinical relevance 
Patient satisfaction measures a specific concept from the patient perspective that is 
obviously clinically relevant. Patient satisfaction can be assessed through specific 
questionnaires developed in the late 1970s (100), which explore multiple domains, 
such as symptoms and functional status, health perception, but also domains related 
to the relationship with nurses, physicians and other health professionals, to personal 
issues, admission, visitors, discharge, room, meals, tests and treatments (98). In the 
setting of ACS, patient information is a major component of patient satisfaction, 
whereby the more information patients receive, the more they report being satisfied 
(99). In a study using data from the CRUSADE registry and including 6467 patients 
with AMI, patient satisfaction was associated with guidelines adherence and with 
mortality rates(97).  
3.6.3. Specific aspects for potential quality indicators 
Given the complexity of assessment of patient satisfaction, the main QI is limited to 
the routine and continuous assessment of patient satisfaction through a specific 
scale. This scale should explore at least 3 domains: (1) pain control, (2) quality of 
information provided by the staff regarding the disease and treatment, and (3) quality 
of discharge explanations and education for secondary prevention and lifestyle.  
3.6.4. Definition of the main and secondary QIs for “patient satisfaction” 
Name of the Feedback regarding patient’s experiences systematically 
collected in an organized way from all patients. It should 
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Main QI (1)  include the following points: 
 Pain control 
 Explanations provided by health professionals about the 
coronary disease, the benefit/risk of discharge 
treatment, and medical follow-up 
 Discharge information regarding what to do in case of 
recurrence of symptoms and recommendation to attend 
a cardiac rehabilitation program (including smoking 
cession and diet counseling) 
 
3.6.5. Agreement with guidelines and existing quality indicators 
The ESC NSTE-ACS guidelines recognized the need to consider patients’ 
preferences for the decision regarding invasive strategy and revascularization, 
particularly in older patients. Pain control is usually not an issue for NSTEMI patients. 
In STEMI patients, relief of pain is considered of paramount importance, both for 
humane reasons but also to avoid excessive adrenaline activation and anxiety. Use 
of morphine, if needed, has a Class I C recommendation.  
Patient information about the disease, need for treatment compliance, risk factor 
control (like smoking cessation, diet and weight control, physical activity) are 
recommended, as well as education about the recognition of symptoms. 
No existing QI set has incorporated patient satisfaction. Conversely, a large number 
of hospitals routinely assess patient satisfaction. Centres from Medicare and 
Medicaid (CMS) in the United States have developed a national standardized survey 
instrument for measuring patient satisfaction: the Hospital Consumer Assessment of 
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Healthcare Providers and Systems (HCAHPS)(101-103). The United Kingdom’s 
National Health Service Patient Survey also systematically gathers the views of the 
patients about the quality of care they have received 
(http://www.pickereurope.org/wp-
content/uploads/2014/10/Inpatients_2015_spec_v12.pdf?gclid=COWclcmIk8oCFWo
CwwodhRUC0Q).  
 
3.7. Composite quality indicators and outcomes 
3.7.1. Dimensions of care 
Composite QI. In view of the growing interest in quality assessment among 
healthcare providers, insurances, agencies, press and the general public, composite 
quality indicators (CQI) have been developed. A CQI is a combination of two or more 
indicators into a single number to summarize multiple dimensions and to facilitate 
comparisons. In the field of assessment of quality of care, a CQI presents three 
potential advantages. Firstly, it comprehensively represents quality of care, making it 
possible to reduce the information into a single summary. Secondly, the information 
may contain a broader range of measures, including multiple dimensions of care. 
Thirdly, the presentation of the CQI as a single number facilitates its use by providers 
for decision-making, benchmarking or financial incentives. In addition, a CQI reduces 
the visible size of a set of indicators, allowing comparison and categorization of the 
centres, and it can be used to assess progress over time and facilitate 
communication and accountability. The disadvantage of the CQI is that it may be 
misinterpreted and invite simplistic policy conclusions. Another criticism leveled at 
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CQIs is that they can be like a “black box”, with loss of information; moreover, the 
selection of indicators and the models used to construct the CQI can be disputed. 
Despite widespread enthusiasm for the development of CQIs, methodological 
controversies have arisen over their robustness, in the absence of an established 
model. In 2010, the AHA/ACC Task Force on Performance Measures published a 
Position Statement for the creation and interpretation of CQIs in healthcare 
assessment (6). The ACCA Quality of Care Working Group has decided to include 
two CQIs. A first CQI (opportunity-scoring), using a greater number of individual QIs, 
is suitable with a view to promoting high quality standards. The second (all or none) 
is based on discharge treatment, and is suitable for use in survivors and in all 
centres, irrespective of on-site facilities. These CQI can serve as a comparator 
between different healthcare systems or within centres to compare quality over time, 
and to determine categories of centres by comparison with the average value.  
Outcome QI. Although clinical outcome is the final aim of quality of care, the use of 
outcome measures in quality assessment is the subject of controversy, since the 
variation in outcomes only partially depends on the quality of care. Furthermore, 
reporting outcomes might have adverse effects, such as restriction of admission for 
more severe patients. Nevertheless, since outcome measures are the most easily 
interpretable and also potentially important for patients (3), the Quality of Care 
Working Group has decided to include an outcome QI.  
3.7.2. Clinical relevance 
Whereas the relation between a single QI and clinical outcome is difficult to 
demonstrate, the relation between CQI and mortality has been established through 
different approaches. In early studies, a trend towards lower in-hospital mortality was 
observed across categories of centres defined according to the quartiles of a 
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composite indicator (104). Similarly, a significant trend towards lower 30-day 
mortality, adjusted for the GRACE risk score, was also observed at patient level, by 
quartiles of a composite score (105). The strength of association is higher with CQIs 
as compared to individual QIs (104, 106).  
The association between CQIs and mortality has been observed in-hospital, but also 
at 30 days (105-108) and 1 year (106, 108). The magnitude of the relation between a 
CQI and mortality is usually modest, but significant. In a study from the National 
Registry of Myocardial Infarction, 6% of the variance in 30 day mortality after STEMI 
was explained by a CQI including “only” timely reperfusion and smoking measures 
(7). Similarly, the correlation between CQI and mortality (107) or risk adjusted 
mortality (105, 106, 109) is not strong. Indeed, the magnitude of the relation between 
a CQI and mortality depends on the individual QIs used, and on the type of QI.  
3.7.3. Specific aspects for potential quality indicators 
Explicit criteria exist for the development of composite performance measures so that 
they can accurately reflect healthcare quality, including explicit quantification of the 
numerator and denominator of potential measures and explicit evaluation of the 
interpretability, actionability, and feasibility of the proposed measure. Among the 
different methods of aggregation, the “opportunity-based” score (with or without 
weighting) and the “all or none” are the most frequently used in the assessment of 
quality of care. These two methods provide different results and the appropriate 
approach should be selected according to the purpose of the assessment (107, 108, 
110, 111). 
Opportunity Scoring: The main CQI includes all the individual QIs selected by the 
group, including structure, process and patient satisfaction QIs. However, since it is 
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possible that not all the components are available in all centres, the opportunity-
based scoring method has been chosen for the calculation of this CQI, without 
weighting. 
All or None: The secondary CQI included here uses discharge prescriptions, and is 
calculated using the “all or none” method. This method best reflects the interest of the 
patient, since even one missing component in the score may influence outcome. This 
CQI makes it possible to track excellence. For each patient, the CQI is rated 1 if all 
components of the CQI are present and it is rated 0 if one or more components are 
missing. In patients with heart failure or LVEF ≤0.40, the CQI is calculated from five 
individual QIs, and for patients without heart failure or with LVEF >0.40, the CQI is 
calculated using three individual QI. 
30-day mortality rate, adjusted for GRACE risk score: Although there is no question 
as to the importance of outcome in quality of care, the use of outcome QIs is still 
controversial. Limitations on the use of outcomes as QI include the complex and 
multifactorial determinants of outcome, as well as the low proportion of variance in 
outcomes that can be explained by quality of care. The least controversial outcome 
QI in the setting of AMI is the adjusted 30-day mortality. Given the relatively low 30-
day mortality rate after AMI in European countries, reliable assessment of mortality 
rate over a short period of time is challenging. In addition, the risk model used for 
adjustment can influence the results. In their latest position paper, the ACC/AHA 
recognized adjusted 30-day mortality as an acceptable outcome PM (3). Our writing 
group has selected the GRACE risk score for adjustment, since this score has been 
recently updated and validated in European registries and because guidelines 
recommend the calculation of GRACE risk score in patients with NSTEMI (52).  
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3.7.4. Definition of the main and secondary quality indicator for “composite quality 
indicators and outcomes” 
Name of the 
Main CQI 
 Composite QI = Main CQI: Opportunity-based CQI, with 
the following individual indicators:  
o The centre is part of a Network Organization 
o Proportion of patients reperfused among eligible 
(STEMI with FMC <12 hours after onset of pain). 
o Coronary angiography in STEMI and NSTEMI 
patients at high ischaemic risk and without 
contraindications 
o Ischaemic risk assessment using the GRACE risk 
score in NSTEMI patients 
o Bleeding risk assessment using the CRUSADE risk 
score in STEMI and NSTEMI patients 
o Assessment of LVEF before discharge. 
o Low dose aspirin (unless high bleeding risk or oral 
anticoagulation) 
o Adequate P2Y12 inhibition (as defined in treatment 
during hospitalization section)  
o ACEI (or ARBs if intolerant of ACEI, unless contra 
indicated) before discharge in patients with clinical 
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evidence of heart failure or LVEF ≤0.40. 
o beta-Blockers (unless clear contraindication) in 
patients with clinical evidence of heart failure or  
LVEF ≤0.40  
o High intensity statins 
o Feedback regarding the patient’s experience and 
quality of care is systematically collected for all 
patients 
 
 
Name of the 
Secondary CQI 
(1) 
 Secondary CQI: All-or-none CQI based on 3 or 5 
components, according to the LVEF. 
 In patients without heart failure and with LVEF >0.40, 
CQI calculated on 3 individual QI: 
 Low dose aspirin  
 P2Y12 inhibitor (unless documented contraindication) 
 High intensity statins  
 In patients with heart failure or with LVEF ≤0.40, CQI 
calculated on 5 individual QI: 
 Low dose aspirin  
 P2Y12 inhibitor (unless documented contraindication) 
 High intensity statins  
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 ACEI (or ARB if intolerant of ACEI) in patients with 
clinical evidence of heart failure or LVEF ≤0.40 
 Beta-blockers (unless clear contraindication) in 
patients with clinical evidence of heart failure or 
LVEF ≤0.40 
 
Name of the 
secondary QI (2) 
Outcome QI: Risk-adjusted 30-day mortality rate 
adjusted on the GRACE 2.0 risk score. 
 
 
3.7.5. Agreement with existing QI and guidelines:  
Currently, no CQI is included in the ACC/AHA set of PM (8), or in the Canadian PM 
(112). Conversely, CQI are used for assessment of quality of care by the Joint 
Commission on Accreditation of Healthcare Organizations (JCAHO), the Agency for 
Healthcare Research and Quality (AHRQ), the Centers for Medicare and Medicaid 
Services (CMS), the Myocardial Ischemia National Audit Project (MINAP) (108) and 
by the French National Authority for Health (Haute Autorité de Santé) (113).  
Outcome QI: The use of the GRACE 2.0 risk calculator is recommended in the ESC 
guidelines for ischaemic risk assessment and for prognostic assessment in NSTEMI 
patients. The risk-adjusted 30-day mortality rate is recommended by the ACC/AHA 
task force, but is not included in the ACC/AHA QI set. 
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4. Discussion 
The Acute Cardiovascular Care Association (ACCA) brought together the current 
Quality of Care Working Group with a view to defining a set of QIs for the 
management of AMI. This is the first such initiative undertaken within the ESC by one 
of its constituent associations. The absence of any official publication of QIs in 
STEMI and NSTEMI by the ESC to date is in contrast with the historical experience 
of the ACC and AHA in this area (8, 9), and with individual national initiatives. Among 
the missions of the ACCA, “improving the quality of care of patients with acute 
cardiovascular disease” is fundamental, thus justifying the creation of this Working 
Group to define QIs suitable for use in this clinical setting.  
Specificities of the quality indicators defined by the ACCA:  
Compared with previous QIs defined by the ACC-AHA (8, 9), the Canadian 
Cardiovascular Society (40), or the National Service Framework for Coronary Heart 
Disease (114), the selection of suitable QIs by the ACCA Quality of Care Working 
Group followed a methodology that is comparable in many respects, but different on 
a certain number of important points.  
While the QIs developed by our group are in line with the official guidelines published 
by the ESC, they are not simply the reflection of high grade recommendations, but 
rather incorporate measures that have a grade II recommendation, or even no 
recommendation at all, because the Quality of Care Working Group feels that it is a 
critically measurable reflection of the quality of care. Indeed, therein lies the 
difference between guidelines and quality indicators (115). Conversely, some key 
features of management that hold a strong grade recommendation were not retained 
as QI, when it was judged that there was little room for improvement. A typical 
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example of this is the prescription of aspirin at admission or discharge, which is 
among the QIs issued by the ACC-AHA, but registry data show that the already 
widespread implementation of this measure leaves little room to further improve 
practices on this point. Although some of the QIs do not fulfil the criteria for PM, the 
ACCA Quality of Care Working Group decided to keep all selected QIs, even if the 
set of QI might not be suitable for public reporting, benchmarking or Pay for 
Performance. The main reason was that the QI focus on processes of care for which 
failure to follow the recommendations is likely to result in suboptimal patient 
outcomes. 
Another point of divergence between the QIs defined here and previous publications 
from other societies concerns the wide spectrum of topics covered by the ACCA QIs. 
Indeed, seven domains were selected to define one or more main QIs as well as 
secondary QIs. Two domains are related to the organisation at the level of the centre, 
as opposed to the quality of individual management. In particular, the Structure-
Network domain emphasises the importance of the working environment in each 
centre, as this has been clearly shown to have an impact on clinical outcomes in 
STEMI management. Patient satisfaction is the second domain that deals with centre 
organisation rather than individual patterns of care. To date, neither the ACC-AHA 
QIs nor those of the Canadian Cardiovascular Society have defined any indicators 
relating to centre organisation or patient satisfaction. The ACCA Quality of Care 
Working Group considered that certain contributors to patient satisfaction (e.g. pain 
management, respect, education) can reflect the quality of care better than medical 
criteria.  
In the five other domains, the QIs selected by the ACCA Quality of Care Working 
Group present some differences and specificities as compared to existing QIs from 
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other sources. For example, in addition to a QI for reperfusion, a QI for “early 
invasive strategy” has been added, which is applicable to patients with NSTEMI. 
Estimation of the ischaemic and bleeding risks using the GRACE and CRUSADE risk 
scores respectively has been added as a QI, going beyond the simple measure of 
LVEF recommended by American PMs. The QIs related to secondary prevention 
focus on the use of high-intensity statins and on the treatment of patients with a 
LVEF ≤0.40, which are two situations where these treatments are especially 
beneficial. Lastly, the composite criterion proposed in this paper is computed using 
the “opportunity-based” method, based on all the main QIs from all the domains, 
while a second “all or none” composite QI is proposed, with a limited number of QIs 
(108, 116).  
Implementation of QIs 
The QIs defined here by the ACCA Quality of Care Working Group are not intended 
for ranking, benchmarking, or pay-for-performance, but merely in the aim of 
monitoring and improving quality of care through meaningful surveillance, in line with 
the founding principles of quality of care first described by Donabedian in 1966 (10). 
A second major point is the wide spectrum of the care pathway that is covered by the 
different domains, namely centre organisation, risk assessment, acute management 
and secondary prevention through to outcome. A composite indicator is proposed to 
provide a summary indicator for all the information from these different domains.  
In this document, we propose main QIs, and secondary level QIs. A total of 12 main 
QIs are proposed, representing criteria that we consider to be major, requiring 
preferential measurement. The eight secondary QIs are supplementary measures of 
quality that are suitable for use as a complementary approach. In the continuity of 
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this document, the Quality of Care Working Group plans to design a registry 
specifically intended for performance measurement, as well as annual updates of the 
QIs to reflect any changes in ESC guidelines.  
Assessment of QIs and Perspectives 
Among the main characteristics of a QI, feasibility and reliability of the assessment 
are important, and have an impact on the selection of the QI. The ACCA Quality of 
Care Working Group QI set has been defined in this view. To date, national initiatives 
for assessment of quality have used administrative databases, registries (specifically 
designed or not) or observational cohort studies. Across Europe, leading examples 
include the Swedish Web-system for Enhancement and Development of Evidence-
based care in Heart disease Evaluated According to Recommended Therapies 
(SWEDEHEART) registry, which is a comprehensive and voluntary database of all 
patients admitted for ACS in all Swedish hospitals and including approximately 
80,000 new cases per year (117); the Myocardial Ischaemia National Audit Project 
(MINAP) in England and Wales (the participation of all institutions in England and 
Wales is mandatory and MINAP is used as a tool to improve quality of care (118); the 
French registries on Acute ST-elevation or non-ST-elevation myocardial infarction 
(FAST-MI), which consist in one-month snapshot surveys performed every 5 years 
since 1995 (119), Acute Coronary Syndrome Israeli Survey (ACSIS) (120) - biennial 
two-months registries in all Israeli ICCUs (119) and lastly, the German Maximal 
Individual Therapy in Acute Myocardial Infarction (MITRA) and Arbeitsgemeinschaft 
Leitender Kardiologischer Krankenhausärzte (ALKK) registries(121),(121). The 
Spanish Society of Cardiology and of Thoracic and Cardiovascular Care has defined 
quality markers for clinical cardiology, cardiac imaging acute care, interventional 
cardiology, cardiac rehabilitation and cardiac surgery (122). The proposed indicators 
51 
 
for AMI are in line with the ACCA selection, but not precisely defined, and limited to 
direct transfer for PCI and recording first medical contact to balloon time for STEMI 
patients, risk assessment, revascularization for high risk patients and adherence to 
guidelines for discharge treatment. Several other European countries have 
successfully implemented large-scale population-based registries to collect 
information about the incidence, management and outcome of ACS, such as the 
Acute Myocardial Infarction and Unstable Angina in Switzerland (AMIS plus) 
registry(123), the Italian BLITZ registry (124), the PRIAMHO I and II (125) in Spain 
and in the Central and Eastern European countries (126). Registries for assessment 
of quality have also been organized by the ESC, such as the Euro Heart Survey-ACS 
programme (88, 90, 127). Results from specific European national campaigns using 
quality indicators or QIs have also been reported (113). 
5.Conclusions 
In agreement with the missions of the ACCA, the Quality of Care Working Group has 
planned a quality assessment programme through a dedicated registry using the 
main and secondary QI developed here. Despite its limitations, the publication of this 
set of QI will offer the possibility to assess the quality of management of AMI, which 
in turn will provide a clear picture of the management of AMI in Europe and serve to 
identify the domains of care where improvements are most needed.  
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Table 1: List, area of expertise and participation in QI domains of the members of the 
Quality of Care Working Group (by order of authorship). 
Table 2: Summary of the Quality Indicators: definition, numerator and denominator, 
rationale, support from guidelines and method of reporting. 
 
Figure: Summary of the Quality Indicators: definition, and support from guidelines 
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Table
Table 2: Summary of the Quality Indicators: definition, numerator and denominator, 
rationale, support from guidelines and method of reporting 
 
1.1. Centre Organization. Main QI:The centre should be part of a Network Organization 
with written protocols for rapid and efficient management covering the following 
points: 
 Single emergency phone number for the patient to be connected with a medical 
system for triage. 
 Pre-hospital interpretation of ECG for diagnosis and decision for immediate transfer 
to a center with catheterization laboratory facilities. 
 Pre-hospital activation of the catheterization laboratory. 
Numerator: All centres that are part of a Network Organization 
Denominator: All centres.  
Clinical rationale: To improve speed and efficiency of pre-hospital care and reperfusion for 
STEMI patients  
Sources of Data: Administrative data 
Corresponding guidelines: 
 Network organization: ESC STEMI GL Class I, level B,  
 Written protocol: ESC STEMI GL Class I, level C. 
 Single phone call: no recommendation. 
 Pre hospital interpretation of ECG: ESC STEMI GL Class I, level B. 
 Pre hospital activation of the catheterization laboratory: ESC STEMI GL Class IIa, level 
B. 
Method of reporting: Qualitative measure per centre. 
 
1.2. Centre Organization. Secondary QI (1): Routine assessment of relevant times for the 
reperfusion process in STEMI patients (i.e. times from “call to first medical contact”, 
“first medical contact to door”, “door to device”; and “door-in door-out” for centers 
without a catheterization laboratory on site). 
Numerator: All centres with routine assessment of relevant intervals for the reperfusion 
process. 
Denominator: All centres. 
Clinical rationale: To identify system inefficiencies and steps where reduction in time for 
reperfusion for STEMI patients is possible. 
Sources of Data: Administrative data.  
Corresponding guidelines:  
Table2
 Routine assessment of time to reperfusion for STEMI patients (time “call to first 
medical contact”, first medical contact to door”, door to device”): ESC STEMI GL, 
Class I, level C 
 All hospital must record and monitor delay times: ESC STEMI GL, Class I, level B  
Method of reporting: Qualitative measure (per centre). 
 
1.3. Centre Organization. Secondary QI (2):The centre should participate in a regular 
registry or program for quality assessment. 
Numerator: Centres participating in a registry.   
Denominator: All centres. 
Clinical rationale: To allow assessment of quality of care.    
Sources of Data: Administrative data, Registry data. 
Corresponding guidelines:  
 The center should participate regularly in a registry for quality assessment: ESC STEMI 
GL, Class I, level C 
 Development of regional or national programmes to measure performance indicators 
systematically and provide feedback to individual hospitals : proposed as  PM by ESC 
GL NSTE-ACS  
Method of reporting: Qualitative measure (per centre). 
 
 
2.1. Reperfusion-Invasive Strategy. Main (STEMI 1):Proportion of STEMI patients reperfused 
among those eligible (onset of symptoms to diagnosis <12h) 
Numerator: Number of STEMI patients with onset of symptoms to diagnosis <12h who 
receive reperfusion therapy 
Denominator: All STEMI patients eligible for reperfusion (onset of symptoms to diagnosis 
<12h, without contraindication or patient refusal). 
Clinical rationale: All STEMI patients (within the first 12 hours) should receive reperfusion 
therapy. 
Sources of Data: Administrative data and medical records. 
Corresponding guidelines: ESC STEMI GL:Reperfusion <12 hours: Class I, level A. 
Method of reporting: Proportion (standard error). 
 
2.2. Reperfusion-Invasive Strategy. Main QI (STEMI 2): Proportion of patients with timely 
reperfusion. Timely is defined as: 
• For patients treated with fibrinolysis: < 30 mins from diagnosis (FMC) to needle  
• For patients treated with primary PCI and admitted to centres with catheterization 
laboratory facilities: < 60 mins from door to balloon (passage of wire) for 
reperfusion with PCI 
•  For transferred patients: door-in door-out time of < 30 mins  
Numerator: Number of STEMI patients treated with primary PCI within the above delays 
Denominator: All STEMI patients eligible for reperfusion by primary PCI (onset of symptoms 
to diagnosis <12h, without contraindication or patient refusal). 
Clinical rationale: Time to effective mechanical reperfusion should be reduced. 
Sources of Data: Pre-hospital and hospital medical records, ECG, angiography. 
Corresponding guidelines:Timely reperfusion:  
• For patients treated with fibrinolysis: < 30 min FMC to needle: ESC STEMI GL, class I, 
level B 
• For patients admitted to centers with catheterization laboratory facilities: <60 min 
door to balloon (passage of wire) for reperfusion with PCI ESC STEMI GL, class I, level 
B 
• For patients transferred to a non PCI-capable centre for primary PCI : should bypass 
the emergency department… : ESC STEMI GL, Class IIa, level B. <30 mins door-in-door 
out: ESC Revascularization GL, Class IIa, level B.  
Method of reporting: Proportion (standard error). 
2.3. Reperfusion-Invasive Strategy. Main QI (NSTEMI): Proportion of patients with NSTEMI 
and no contra indication who receive coronary angiography within 72 hours after 
admission. 
Numerator: Number of NSTEMI patients at high-intermediate ischemic risk undergoing 
coronary angiography within 72 hours after the diagnosis. 
Denominator: All NSTEMI patients at high-intermediate ischemic risk without 
contraindications or patient refusal. 
Clinical rationale: NSTEMI patients at high risk should be treated with early invasive 
strategy. Early is defined as ≤ 72 hours after admission 
Sources of Data: Medical records, ECG, angiography. 
Corresponding guidelines: Invasive strategy ≤ 72 hours for high-intermediate risk (in patients 
with NSTEMI and one intermediate-risk criteria (diabetes mellitus, renal dysfunction 
(eGFR<30 ml/min/1.72m²), LVEF ≤ 0.40, congestive heart failure, recent PCI, prior CABG, 
GRACE risk score >140) or recurrent symptoms or ischaemia on non invasive testing: ESC  
NSTE-ACS GL Class I, level A. 
Method of reporting: Proportion (standard error). 
2.4. Reperfusion-Invasive Strategy. Secondary QI (STEMI): The time between the diagnosis 
(FMC) and passage of wire (absolute value) for primary PCI. 
Clinical rationale: Improve speed and efficiency of pre-hospital care and reperfusion for 
STEMI patients. 
Sources of Data: Pre-hospital and hospital medical records, ECG, angiography. 
Corresponding guidelines: ESC Guidelines for STEMI 2012: Routine assessment of times for 
reperfusion: Class I, level B 
Method of reporting: Median time 
 
3.1.In Hospital Risk Assessment. Main QI (1): The proportion of patients with NSTEMI in 
whom ischaemic risk assessment using the GRACE risk score is performed. GRACE score 
should be assessed and the numerical value of the score recorded for all patients admitted 
with suspected NSTEMI.  
Numerator: Number of NSTEMI patients who have been stratified according to the GRACE 
risk score.   
Denominator: Number of NSTEMI patients.  
Clinical rationale: NSTEMI patients at high ischemic risk should be treated with early 
invasive strategy. 
Sources of Data: Medical records. 
Corresponding guidelines:  
 Prognostic risk assessment: The use of risk scores for estimating prognosis is 
recommended:ESC NSTE-ACS GL, Class I, level A 
 GRACE score: Recommendations Class IA depending on the value of the GRACE score.  
 
Method of reporting: Proportion (standard error). 
 
3.2.In Hospital Risk Assessment.Main QI (2): Proportion of patients admitted with STEMI or 
NSTEMI who have bleeding risk assessment using the CRUSADE bleeding score. The 
CRUSADE bleeding score should be assessed and the numerical value of the score recorded 
for all patients admitted with STEMI or NSTEMI. 
Numerator: Number of STEMI or NSTEMI patients who have been stratified according to the 
CRUSADE bleeding score.   
Denominator: Number of STEMI or NSTEMI patients. 
Clinical rationale: STEMI and NSTEMI patients at high bleeding risk should be treated with 
caution regarding anti thrombotic treatment.  
Sources of Data: Medical records. 
Corresponding guidelines: 
 Prognostic risk assessment: ESC NSTE-ACS GL Class I, level A. 
 CRUSADE bleeding score: ESC NSTE-ACS GL: Class IIb, level B. 
 
Method of reporting: Proportion (standard error). 
 
3.3.In Hospital Risk Assessment.Main QI (3): Proportion of patients with assessment of LVEF 
before discharge. LVEFshould be assessed and the numerical value recorded for all 
patients admitted with STEMI or NSTEMI. 
Numerator: Number of AMI patients with measured LVEF. 
Denominator: All AMI patients. 
Clinical rationale: All AMI patients with LVEF ≤ 0.40 need specific medical treatment. 
Sources of Data: Medical records, echocardiogram, ECG. 
Corresponding guidelines:  
 LVEF assessment: ESC STEMI GL Class I, level A. 
 LVEF assessment: ESC NSTE-ACS GL Class I, level C. 
 
Method of reporting: Proportion (standard error). 
 
4.1. Anti thrombotics during hospitalization. Main QI (1): Proportion of patients with 
“adequate P2Y12 inhibition” defined as: (number of patients discharged with prasugrel or 
ticagrelor or clopidogrel) / (patients eligible). Eligible is defined as follows:  
o For ticagrelor: AMI patients without previous haemorrhagic stroke, high 
bleeding risk, fibrinolysis or oral anticoagulation. 
o For prasugrel: PCI-treated AMI patients without previous haemorrhagic or 
ischemic stroke, high bleeding risk (patients ≥75 years and/or <60 kg body 
weight are also considered as high bleeding risk), fibrinolysis or oral 
anticoagulation.   
o For clopidogrel: no indication for prasugrel or ticagrelor and no high bleeding 
risk. 
Numerator: Number of STEMI and NSTEMI patients with “adequate P2Y12 inhibitor” at 
discharge. 
Denominator:STEMI and NSTEMI patients alive at discharge and without contraindications 
to P2Y12 inhibitors 
Clinical rationale: Superiority of prasugrel and ticagrelor over clopidogrel in selected 
patients. 
Sources of Data: Medical records. 
Corresponding guidelines: ESC STEMI, ESC NSTE-ACS and ESC revascularization GL: 
 Eligibility for Ticagrelor: Class I, level B. 
 Eligibility for Prasugrel: Class I, level B. 
 Eligibility for Clopidogrel: Class I, level A. 
 
Method of reporting: Proportion (standard error). 
4.2. Anti thrombotics during Hospitalization. Main QI (2): Proportion of patients with 
NSTEMI treated with fondaparinux, unless candidate for immediate (≤2 hours) invasive 
strategy or with eGFR < 20 ml/min. 
 Numerator: Number of NSTEMI patients with eGFR ≥ 20 ml/min, not candidates for 
urgent invasive strategy, treated with fondaparinux. 
Denominator: All NSTEMI patients with eGFR ≥ 20 ml/min, not candidates for urgent 
invasive strategy. 
Clinical rationale: Better risk / benefit profile of fondaparinux in NSTEMI patients. 
Sources of Data: Medical records. 
Corresponding guidelines: Fondaparinux most favorable risk benefit profile (for NSTEMI 
patients not candidate for urgent angiography): ESC NSTE-ACS and Revascularization GL 
Class I, level B. 
Method of reporting: Proportion (standard error). 
4.3.Anti thrombotics during Hospitalization. Secondary QI: Proportion of patients 
discharged on dual antiplatelet therapy, defined as: (number of patients discharged on 
dual antiplatelet therapy) / (number of patients with AMI without clear and documented 
contraindication). 
Numerator: Number of STEMI and NSTEMI patients, without contra indication, discharged 
with dual antiplatelet therapy.  
Denominator: All STEMI and NSTEMI patients, without contra indications to dual antiplatelet 
therapy. 
Clinical rationale: Benefit of DAPT over single antiplatelet therapy for 12 months. 
Sources of Data: Medical records. 
Corresponding guidelines: Irrespective of the revascularization strategy, a P2Y12 inhibitor is 
recommended in addition to aspirin for patients with AMI: ESC STEMI GL, Class I, level A;ESC 
NSTE-ACS GL, Class I, level A. 
 
Method of reporting: Proportion (standard error). 
5.1. Secondary Prevention-Discharge Treatment. Main QI (1): Proportion of patients with 
AMI discharged on statins, unless contra indicated, at high intensity (defined as 
atorvastatin ≥40 mg or rosuvastatin ≥20 mg). 
Numerator:The number of patients with AMI who receive high intensity statin therapy at 
discharge 
Denominator:STEMI and NSTEMI patients alive at discharge and without contraindications, 
refusal, side effects, allergy, or history of intolerance to high-intensity statin therapy.  
Clinical rationale: The use of high intensity statins is associated with reduced risk of 
recurrent cardiovascular events and mortality following AMI. 
Sources of Data: Medical records. 
Corresponding guidelines: Statins high intensity as early as possible, unless contra 
indication: ESC STEMI GL, Class I, level A, ESC NSTE-ACS GL, Class I, level A 
Method of reporting: Proportion (standard error). 
5.2. Secondary Prevention-Discharge Treatment. Secondary QI (1): Proportion of patients 
with AMI and clinical evidence of heart failure or a LVEF ≤0.40 who are discharged on ACEI 
(or ARBs if intolerant of ACEI) unless contraindicated.  
Numerator:The number of patients with AMI who have heart failure or a LVEF < 0.40, and 
who receive an ACEI/ARB before discharge.  
Denominator: All AMI patients who have heart failure or a LVEF< 0.40, and who are eligible 
for ACEI/ARBs (no hypotension, acute renal failure, hyperkalemia, contraindications, refusal, 
side effects or allergy). 
Clinical rationale: The use of ACEIs/ARBs is associated with reduced mortality following AMI 
in patients with heart failure or left ventricular systolic dysfunction. 
Sources of Data: Medical records. 
Corresponding guidelines:ACE inhibitor in patients with LVEF ≤ 0.40 or heart failure, 
hypertension or diabetes: ESC STEMI GL, class I, level A, ESC NSTE-ACS GL Class I, level A 
Method of reporting: Proportion (standard error). 
5.3.Secondary Prevention-Discharge Treatment. Secondary QI (2): Proportion of patients 
with AMI and clinical evidence of heart failure or an LVEF ≤ 0.40 who are discharged on 
beta-blockers, unless contraindicated. 
Numerator: The number of patients with AMI who have heart failure or a LVEF≤0.40 and 
receive a beta-blocker before discharge.  
Denominator: All AMI patients who have heart failure or a LVEF< 0.40, and are eligible for 
beta-blockers (no evidence of a low output state, increased risk for cardiogenic shock, PR 
interval >  0.24 seconds, second- or third-degree heart block, active asthma, or reactive 
airways disease).   
Clinical rationale: The use of beta-blockers in patients with AMI and who have heart failure 
or left ventricular systolic dysfunction is associated with a mortality benefit. 
Sources of Data: Medical records. 
Corresponding guidelines: Beta-blocker therapy in patients with LVEF ≤ 0.40, unless 
contraindicated: ESC STEMI GL, Class I, level A, ESC NSTE-ACS GL, Class I, level A 
Method of reporting: Proportion (standard error). 
6.1. Patient satisfaction. Main QI: Feedback regarding the patient’s experience 
systematically collected in an organized way from all patients. It should include the 
following points: 
 Pain control. 
 Explanations provided by doctors and nurses (about the coronary disease, the 
benefit/risk of the discharge treatment, and medical follow-up). 
 Discharge information regarding what to do in case of recurrence of symptoms and 
recommendation to attend a cardiac rehabilitation program (including smoking 
cessation and diet counseling). 
Numerator: Number of STEMI and NSTEMI patients discharged alive with feedback 
collected.   
Denominator: STEMI and NSTEMI patients discharged alive.   
Clinical rationale: Patient satisfaction must be considered in assessment of quality of care. 
Relation between patient satisfaction and adherence to guidelines, and with mortality. 
Sources of Data: Administrative data and medical records. 
Corresponding guidelines: No ESC GL to support this QI.  Review paper by Anker et al 
published in Eur Heart J in 2014 
 Participation in a well-structured cardiac rehabilitation programme: ESC NSTE-ACS 
GL, Class IIa, level A 
 Smoking cessation advice/counselling: ESC STEMI GL, class I, level C; proposed as PM 
by ESC GL NSTE-ACS 2015, no recommendation 
 Enrollment in a secondary prevention /cardiac rehabilitation programme: : proposed 
as PM by ESC NSTE-ACS GL, 2015, no recommendation 
Method of reporting: Proportion (standard error). 
 
7.1.Composite QI. Main Composite QI: Opportunity based CQI, with the following individual 
indicators:  
• The center is part of a network organization 
• Proportion of patients reperfused among eligible (STEMI with FMC <12 hours after 
onset of pain) 
• Coronary angiography in STEMI and NSTEMI patients at high ischaemic risk and 
without contraindications 
• Ischemic risk assessment using the GRACE risk score in NSTEMI patients 
• Bleeding risk assessment using the CRUSADE risk score in STEMI and NSTEMI 
patients 
• Assessment of LVEF before discharge 
• Low dose aspirin (unless high bleeding risk or oral anticoagulation) 
• Adequate P2Y12 inhibition (as defined in the treatment during hospitalization 
section) 
• ACEI (or ARB if intolerant of ACEI) in patients with clinical evidence of heart failure 
or an LVEF ≤0.40  
• Beta-blockers (unless clear contraindication) in patients with clinical evidence of 
heart failure or an LVEF ≤0.40 
• High intensity statins  
• Feedback regarding the patient’s experience and quality of care is systematically 
collected for all patients. 
Numerator: all AMI patients discharged: sum of points (one point for each individual 
indicator, all individual indicators are weighted equally)  
Denominator: All AMI patients discharged: sum of points (one point for each applicable 
indicator, according to patient and centre characteristics). 
Clinical rationale: Relation between CQI and mortality. 
Sources of Data: Administrative data and Medical records, statistical computation. 
Corresponding guidelines: no Recommendation. 
 
Method of reporting: Mean value (95% confidence interval). 
 
7.2. Composite QI. Secondary Composite QI: All-or-none CQI based on 3 or 5 components, 
according to the LVEF. 
Calculated on 3 individual QIs in patients without heart failure and with LVEF >0.40.  
o Low dose aspirin  
o P2Y12 inhibitor (unless documented contraindication) 
o High intensity statins 
 
Calculated on 5 individual QIs in patients with heart failure or with LVEF ≤ 0.40. 
o Low dose aspirin  
o P2Y12 inhibitor (unless documented contraindication) 
o High intensity statins  
o ACEI (or ARB if intolerant to ACEI) in patients with clinical evidence of heart 
failure or LVEF ≤0.40  
o Beta-blockers (unless clear contraindication) in patients with clinical evidence of 
heart failure or LVEF ≤0.40 
 
Clinical rationale: Relation between CQI and mortality. 
Sources of Data: Medical records, Statistical computation. 
Corresponding guidelines: no Recommendation. 
Method of reporting: At patient level, can be 0 or 1. At centre level, mean value (95% 
confidence interval). 
7.3. Outcome QI. Secondary Outcome QI: 30-day mortality rate adjusted for the GRACE 2.0 
risk score. 
Numerator: All AMI patients who died within 30 days after admission, with assessment of 
the GRACE risk score. 
Denominator: All AMI patients with assessment of the GRACE risk score and 30 day follow-
up. 
Sources of Data: Medical records, registry data. 
Clinical rationale: 30 day adjusted mortality is an established criterion for quality of care in 
AMI patients. 
Corresponding guidelines: no Recommendation. 
Method of reporting: Proportion (standard error). 
 
Domain of Care Quality Indicator Support from ESC guidelines
Center 
Organization
Main QI: The centre should be part of a Network Organization with written protocols 
for rapid and efficient management covering the following points:
•Single emergency phone number for the patient to be connected to a medical system 
for triage 
•Pre-hospital interpretation of ECG for diagnosis and decision for immediate transfer 
to a center with catheterization laboratory facilities
•Pre-hospital activation of the catheterization laboratory 
Secondary QI (1): Routine assessment of relevant times for the reperfusion process in 
STEMI patients (i.e. times from “call to first medical contact”, “first medical contact to 
door”, “door to device” and “door-in door-out” for centers without a catheterization 
laboratory on site).
Secondary QI (2): The center should participate in a regular registry or program for 
quality assessment.
Network: ESC GL, Class I, level B 
Written protocol: ESC STEMI GL Class I, level C
Single phone number : No ESC GL to support this QI. 
Pre hospital interpretation of ECG: ESC STEMI GL, Class I level B
Pre hospital easy activation of the catheterization laboratory : ESC STEMI GL, level  B 
Routine assessment of time to reperfusion for STEMI patients (time “call to first medical 
contact”, first medical contact to door”, door to device”): ESC STEMI GL, Class I, level C
All hospital must record and monitor delay times: ESC STEMI GL, Class I, level B 
The center should participate regularly in a registry for quality assessment: ESC STEMI GL, 
Class I, level C
Development of regional or national programmes to measure performance indicators
systematically and provide feedback to individual hospitals : proposed as  PM by ESC GL 
NSTE-ACS 2015
Reperfusion-
Invasive 
Strategy
Main QI (STEMI 1): Proportion of STEMI patients reperfused among eligible (onset of 
symptoms to diagnosis <12h) 
Main QI (STEMI 2): Proportion of patients with timely reperfusion. Timely is defined 
as:
• For patients treated with fibrinolysis: < 30 mins from diagnosis (FMC) to needle 
• For patients treated with primary PCI and admitted to centres with catheterization 
laboratory facilities: < 60 mins from door to balloon (passage  of wire) for reperfusion 
with PCI
• For transferred patients: door-in door-out time of < 30 mins
Secondary QI (STEMI): the time between the diagnosis (FMC) and passage of wire
time (absolute value) for primary PCI.
Main QI (NSTEMI): Proportion of patients with NSTEMI, and no contra-indication, who 
receive coronary angiography within 72 hours after admission.
Reperfusion STEMI patients Onset up to 12h: ESC STEMI GL, Class I, level A
Timely reperfusion: 
• For patients treated with fibrinolysis: < 60 min FMC to needle: ESC STEMI GL, class I, 
level B
• For patients admitted to centers with catheterization laboratory facilities: <60 min 
door to balloon (passage of wire) for reperfusion with PCI ESC STEMI GL, class I, level B
• For patients transferred to a non PCI-capable centre for primary PCI :
should bypass the emergency department… : ESC STEMI GL, Class IIa, 
level B 
<30 mins door-in-door out: ESC Revascularization GL, Class IIa, level B. 
All hospitals must record and monitor delay times: ESC STEMI GL, Class I, level B 
Invasive strategy in moderate-high risk patients: ESC NSTE-ACS GL, Class I, level A
In Hospital Risk 
Assessment
Main QI (1): Proportion of patients with NSTEMI who have ischaemic risk assessment 
using the GRACE risk score. GRACE risk score should be assessed and the numerical 
value of the score recorded for all patients admitted with suspected NSTEMI.
Main QI (2): Proportion of patients admitted with STEMI and NSTEMI who have   
bleeding risk assessment using the CRUSADE bleeding score. The CRUSADE bleeding 
score should be assessed and the numerical value of the score recorded for all patients 
admitted with STEMI and NSTEMI.
Main QI (3): Proportion of patients with STEMI and NSTEMI who have assessment of 
left ventricular ejection fraction. Left ventricular ejection fraction should be assessed 
and the numerical value recorded for all patients admitted with STEMI and NSTEMI. 
The use of risk scores for estimating prognosis is recommended: ESC NSTE-ACS GL, Class I, 
level A
Use of the CRUSADE score…in patients undergoing coronary angiography: ESC NSTE-ACS GL 
Class IIb, level B
Assessment of left ventricular ejection fraction: ESC STEMI GL class I, level B
ESC NSTE-ACS GL class I, level B 
Figure
Domain of Care Quality Indicator Support from ESC guidelines
Anti 
thrombotics 
during 
Hospitalization
Main QI (1): Proportion of patients with “adequate P2Y12 inhibition” defined as: number 
of patients discharged with prasugrel or ticagrelor or clopidogrel / patients eligible. 
Eligible is defined as follows: 
For ticagrelor: AMI patients without previous haemorrhagic stroke, high bleeding risk, 
fibrinolysis or oral anticoagulation
For prasugrel: PCI treated AMI patients without previous haemorrhagic or ischaemic
stroke, high bleeding risk (patients ≥75 years or <60 kg body weight are also considered 
as high bleeding risk), fibrinolysis or oral anticoagulation  
For clopidogrel: No indication for prasugrel or ticagrelor and no high bleeding risk
Main QI (2): Proportion of patients with NSTEMI treated with fondaparinux, unless 
candidates for immediate (≤ 2 hours) invasive strategy, or with eGFR ≥ 20 ml/min .
Secondary QI : Proportion of patients with AMI discharged on dual antiplatelet therapy 
/ patients with AMI without clear and documented contra-indication
Ticagrelor in absence of contra indication for all patients regardless of initial strategy (i.e. 
patients without previous hemorrhagic stroke, high bleeding risk, oral anticoagulation ) 
ESC NSTE-ACS GL, Class I, level B 
Prasugrel: in patients without previous hemorrhagic or ischemic stroke, high bleeding risk 
(patients ≥75 years, <60 kg body weight are also considered as high bleeding risk), oral 
anticoagulation, treated with PCI. ESC NSTE-ACS GL, Class I, level B
Clopidogrel…. for patients who cannot receive ticagrelor or prasugrel or who require oral 
anticoagulation: ESC NSTE-ACS GL, Class I, level B
Fondaparinux is recommended as having the most favourable efficacy/safety profile 
regardless of the management strategy ESC NSTE-ACS GL, Class I, level B
Irrespective of the revascularization strategy, a P2Y12 inhibitor is recommended in 
addition to aspirin for patients with AMI…:ESC STEMI GL, Class I, level A, ESC NSTE-ACS 
GL, Class I, level A.  
Secondary 
Prevention-
Discharge 
Treatment
Main QI: Proportion of patients with AMI discharged on statins, unless contra indicated, 
at high intensity (defined as atorvastatin ≥40 mg or rosuvastatin ≥20 mg).
Secondary QI (1): Proportion of patients with  AMI and clinical evidence of heart failure 
or a LVEF ≤ 0.40 who are discharged on ACEI (or ARBs if intolerant of ACEI) unless 
contraindicated. 
Secondary QI (2): Proportion of patients with  AMI  and clinical evidence of heart failure 
or a LVEF ≤ 0.40 who are discharged on β-Blockers, unless contraindicated. 
Statins high intensity as early as possible, unless contra indication: ESC STEMI GL, Class I, 
level A, ESC NSTE-ACS GL, Class I, level A
Betablocker therapy in patients with LVEF ≤ 0.40, unless contraindicated: ESC STEMI GL, 
Class I, level A, ESC NSTE-ACS GL, Class I, level A
ACE inhibitor in patients with LVEF ≤ 0.40 or heart failure, hypertension or diabetes: ESC 
STEMI GL, class I, level A, ESC NSTE-ACS GL Class I, level A
Use of aspirin, ticagrelor/prasugrel/clopidogrel, statins, betablocker and ACE inhibitor (in 
patients with LVEF≤ 0.40  or heart failure), enrollment in cardiac rehabilitation at 
discharge : proposed as PM by ESC GL NSTE-ACS 2015, no recommendation
Patient 
satisfaction
Main QI: Feedback regarding the patient’s experience is systematically collected for all 
patients. This should include the following points:
•Pain control
•Explanations provided by doctors and nurses (about the coronary disease, the 
benefit/risk of the discharge treatment, and medical follow-up)
•Discharge information regarding what to do in case of a recurrence of symptoms and 
recommendation to attend a cardiac rehabilitation program (including smoking cession 
and diet counseling)
No ESC GL to support this QI. 
Review paper from Anker et al published in Eur Heart J in 2014
Participation in a well-structured cardiac rehabilitation programme: ESC NSTE-ACS GL, 
Class IIa, level A
Smoking cessation advice/counselling: ESC STEMI GL, class I, level C; proposed as PM by 
ESC GL NSTE-ACS 2015, no recommendation
Enrollment in a secondary prevention /cardiac rehabilitation programme: : proposed as 
PM by ESC NSTE-ACS GL, 2015, no recommendation
Domain of Care Quality Indicator Support from ESC guidelines
Composite and 
outcome  QI
Main CQI : Opportunity based CQI, with the following individual indicators: 
•The center is part of a network organization
•Proportion of patients reperfused among eligible (STEMI with FMC <12 hours after 
onset of pain)
•Coronary angiography in STEMI and NSTEMI patients at high ischaemic risk and without 
contraindications
•Ischemic risk assessment using the GRACE risk score in NSTEMI patients
•Bleeding risk assessment using the CRUSADE risk score in STEMI and NSTEMI patients
•Assessment of LVEF before discharge
•Low dose aspirin (unless high bleeding risk or oral anticoagulation)
•Adequate P2Y12 inhibition (unless documented contraindication)
•ACEI (or ARB if intolerant of ACEI) in patients with clinical evidence of heart failure or 
an LVEF ≤0.40 
•β-Blockers (unless clear contraindication) in patients with clinical evidence of heart 
failure or an LVEF ≤0.40
•High intensity statins 
•Feedback regarding the patient’s experience and quality of care is systematically 
collected for all patients.
Secondary CQI: All or none CQI based on 3 or 5 components, according to the LVEF. 
-In patients without heart failure and with LVEF >0.40, CQI calculated on 3 individual 
QI. 
•Low dose aspirin
•P2Y12 inhibitor (unless documented contraindication)
•High intensity statins 
-In patients with heart failure or with LVEF ≤0.40, CQI calculated on 5 individual QI. 
•Low dose aspirin
•P2Y12 inhibitor (unless documented contraindication)
•High intensity statins 
•ACEI (or ARB if intolerant of ACEI) in patients with clinical evidence of heart failure or 
an LVEF ≤0.40
•β-Blockers (unless clear contraindication) in patients with clinical evidence of heart 
failure or an LVEF ≤0.40
Secondary Outcome QI: 30 day mortality rate, adjusted for the GRACE 2.0 risk score
No ESC GL to support this QI. 
ESC NSTE-ACS GL proposes “Performance Measures”, but only individual indicators, no 
composite indicator.
